Live Breaking News & Updates on Mrna 1283

Stay informed with the latest breaking news from Mrna 1283 on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mrna 1283 and stay connected to the pulse of your community

Moderna receives a $750M infusion from Blackstone

Blackstone Life Sciences made an investment of up to $750 million in Moderna Inc.’s influenza program created with its mRNA technology. The new funding is designed to help propel the program forward and may help bolster a stock that has struggled in the past 12 months.

Blackstone-life-sciences , Moderna-inc , Moderna-inc- , Influenza , Mrna , Bioworld , Financings , Infection , Vaccine , Mrna-1283 , Covid-19

Moderna's new COVID-19 vaccine shows promising results in Phase 3 trial, company says

Moderna has announced that its next-generation COVID-19 vaccine, mRNA-1283, has successfully met the primary endpoints of its Phase 3 clinical trial.

Cambridge , Cambridgeshire , United-kingdom , Canada , United-states , Health-medical-pharma , Moderna , Bancel , Nc- , Business-finance , Mrna-vaccine

Moderna Starts New COVID-19 Vaccine Trial

Moderna Starts New COVID-19 Vaccine Trial
by Angela Mohan on
March 17, 2021 at 2:17 PM
First participants have been dosed in the Phase 1 study of mRNA-1283, Moderna's next generation COVID-19 vaccine candidate, which will assess the safety and immunogenicity of mRNA-1283.
"We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283," said Stéphane Bancel, Chief Executive Officer of Moderna.
"Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries," Bancel added.

India , Chief-executive-officer , Receptor-binding-domain , N-terminal-domain , India-achieves , Preferred-greeting , Myths-debunkedcoronavirusindian-namaste , Covid-19 , Vaccine-candidate , Moderna , Phase-1-study